Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events

Authors

  • T. Tzellos,

    1. Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany
    2. Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Search for more papers by this author
  • A. Kyrgidis,

    1. Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany
    2. Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Search for more papers by this author
  • A. Trigoni,

    1. State Clinic, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece
    Search for more papers by this author
  • C.C. Zouboulis

    Corresponding author
    1. Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany
    Search for more papers by this author

No abstract is available for this article.

Ancillary